LivaNova Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 3,300

Employees

  • Stock Symbol
  • LIVN

Stock Symbol

  • Investments
  • 20

  • Share Price
  • $90.78
  • (As of Friday Closing)

LivaNova General Information

Description

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Contact Information

Formerly Known As
Cyberonics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 20 Eastbourne Terrace
  • London W2 6LG
  • England, United Kingdom
+44 020
Primary Industry
Therapeutic Devices
Stock Exchange
NAS
Corporate Office
  • 20 Eastbourne Terrace
  • London W2 6LG
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LivaNova Stock Performance

As of 20-Nov-2026, LivaNova’s stock price is $90.78. Its current market cap is $5B with 55.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$90.78 $92.11 $53.48 - $99.38 $5B 55.1M 686K $3.58

LivaNova Financials Summary

As of 30-Sep-2026, LivaNova has a trailing 12-month revenue of $1.51B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 4,049,983 3,200,346 2,848,099 3,174,278
Revenue 1,506,914 1,388,053 1,253,437 1,153,545
EBITDA 202,552 (130,845) 172,449 16,471
Net Income 196,063 (242,471) 63,234 17,546
Total Assets 2,713,124 2,606,053 2,506,389 2,429,563
Total Debt 357,071 433,772 676,773 640,404
Public Fundamental Data provided by Morningstar, Inc. disclaimer

LivaNova Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore LivaNova‘s full profile, request access.

Request a free trial

LivaNova Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is prima
Therapeutic Devices
London, United Kingdom
3,300 As of 2025

Minneapolis, MN
 

Marlborough, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LivaNova Competitors (25)

One of LivaNova’s 25 competitors is Medtronic, a Corporation company based in Minneapolis, MN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Medtronic Corporation Minneapolis, MN
Boston Scientific Corporation Marlborough, MA
Integra LifeSciences Holdings Corporation Princeton, NJ
Penumbra Formerly VC-backed Alameda, CA
Edwards Lifesciences Corporation Irvine, CA
You’re viewing 5 of 25 competitors. Get the full list »

LivaNova Patents

LivaNova Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260207944-A1 Systems and methods for obstructive respiratory event detection and stimulation therapy Pending 17-Jan-2025
WO-2026155984-A1 Systems for obstructive respiratory event detection and stimulation therapy Pending 17-Jan-2025
WO-2026019898-A1 Systems and methods for obstructive respiratory event detection Pending 17-Jul-2024
US-20260021303-A1 Systems and methods for obstructive respiratory event detection and stimulation therapy Pending 17-Jul-2024
US-12569682-B2 Automatic titration with defibrillation sensitivity compensation Active 17-Apr-2023 A61N1/36114
To view LivaNova’s complete patent history, request access »

LivaNova Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LivaNova Investments & Acquisitions (20)

LivaNova’s most recent deal was a Later Stage VC with ShiraTronics for . The deal was made on 11-Aug-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ShiraTronics 11-Aug-2023 Later Stage VC Therapeutic Devices
Cadence Neuroscience 28-Feb-2023 Later Stage VC Therapeutic Devices
ALung 02-May-2022 Merger/Acquisition Other Devices and Supplies
ALung 24-Aug-2021 Later Stage VC Other Devices and Supplies
Noctrix Health 11-Jan-2021 Later Stage VC Therapeutic Devices
You’re viewing 5 of 20 investments and acquisitions. Get the full list »

LivaNova ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

22.12 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view LivaNova’s complete esg history, request access »

LivaNova Exits (5)

LivaNova’s most recent exit was on 11-Jan-2021 from Noctrix Health. The exit was categorized as with 5 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Noctrix Health 11-Jan-2021 Completed
  • 5 buyers
Ceribell 25-Sep-2018 Completed
  • 5 buyers
Apnex Medical 01-Apr-2014 Completed
Cerbomed 01-Sep-2012 Completed
  • 5 buyers
Cardiosolutions 09-Jul-2012 Early Stage VC Completed
  • 3 buyers
To view LivaNova’s complete exits history, request access »

LivaNova Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Livn Uk 2 Co London, United Kingdom 2015
Livn Irishco 2 Unlimited Company Dublin, Ireland 2015
Livanova Poland Warsaw, Poland 2011
Livanova Nederland Amsterdam, Netherlands 1988
Livanova Belgium Zaventem, Belgium 1968

LivaNova FAQs

  • When was LivaNova founded?

    LivaNova was founded in 2015.

  • Where is LivaNova headquartered?

    LivaNova is headquartered in London, United Kingdom.

  • What is the size of LivaNova?

    LivaNova has 3,300 total employees.

  • What industry is LivaNova in?

    LivaNova’s primary industry is Therapeutic Devices.

  • Is LivaNova a private or public company?

    LivaNova is a Public company.

  • What is LivaNova’s stock symbol?

    The ticker symbol for LivaNova is LIVN.

  • What is the current stock price of LivaNova?

    As of 20-Nov-2026 the stock price of LivaNova is $90.78.

  • What is the current market cap of LivaNova?

    The current market capitalization of LivaNova is $5B.

  • What is LivaNova’s current revenue?

    The trailing twelve month revenue for LivaNova is $1.51B.

  • Who are LivaNova’s competitors?

    Medtronic, Boston Scientific, Integra LifeSciences Holdings, Penumbra, and Edwards Lifesciences are some of the 25 competitors of LivaNova.

  • What is LivaNova’s annual earnings per share (EPS)?

    LivaNova’s EPS for 12 months was $3.58.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process